Core Viewpoint - The report highlights the financial performance and operational strategies of Shengda Bio-Pharm Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and profit driven by enhanced management practices and market expansion in the vitamin and bio-preservative sectors [1][3]. Financial Performance - The company's operating income for the first half of 2025 reached approximately 400.73 million RMB, representing a 4.23% increase compared to the same period last year [3]. - Total profit amounted to approximately 50.27 million RMB, a substantial increase of 107.77% year-on-year [3]. - The net profit attributable to shareholders was approximately 37.81 million RMB, reflecting a 129.20% increase compared to the previous year [3]. - The net cash flow from operating activities was approximately 22.96 million RMB, up 97.59% from the previous year [3]. Industry Overview - The vitamin industry in China is experiencing steady growth, with the country being a major global producer of various vitamins, including biotin and folic acid [6][8]. - The bio-preservative and functional ingredient market is expanding rapidly, driven by increasing consumer demand for natural and safe food additives [6][8]. - The report indicates that the domestic vitamin market faced price declines in the first half of 2025, but the overall demand remains stable [6][8]. Company Positioning - Shengda Bio-Pharm is recognized as one of the leading suppliers of biotin and folic acid in China, ranking among the top five suppliers of biotin and top four suppliers of folic acid in 2024 [6][8]. - The company is one of the few in China capable of producing multiple types of bio-preservatives, including nisin and natamycin, and is a key player in setting industry standards [6][8]. - Shengda Bio-Pharm has established a strong reputation in the market, supported by long-term partnerships with major domestic and international clients [11][12]. Operational Strategies - The company employs a "sales-driven production" model, optimizing procurement and production processes to enhance efficiency and reduce costs [7][8]. - Shengda Bio-Pharm has invested in smart manufacturing technologies to improve product consistency and operational efficiency [7][8]. - The company is focused on continuous innovation and R&D, with a significant increase in R&D expenditure by 22.39% in the first half of 2025 [3][8]. Market Expansion - The company has successfully registered its biotin products in India, the EU, and South Korea, paving the way for entry into higher-end pharmaceutical markets [8][9]. - Shengda Bio-Pharm's subsidiaries have shown strong performance, with significant sales growth in key products such as lactic acid bacteria and natamycin [8][9].

证券代码：603079 证券简称：圣达生物 公告编号：2025-048 浙江圣达生物药业股份有限公司 2025年第二季度主要经营数据公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、报告期内主要产品销售地区分布基本情况 三、报告期内主要产品和原材料的价格变动情况 1、主要产品价格（不含税）变动情况 第二季度，公司主要产品维生素平均销售价格较上年同期上涨45.78%，环 单位：万元 主要产品 营业收入 （境内） 较上年同期 增减（%） 营业收入 （境外） 较上年同期 增减（%） 维生素 2,034.59 8.40 3,156.76 -28.87 生物保鲜剂及功 能配料 10,119.57 3.95 2,331.89 34.04 根据上海证券交易所《上市公司自律监管指引第3号行业信息披露：第十三 号——化工》（2022年修订）及《上市公司自律监管指引第3号行业信息披露： 第十四号——食品制造》（2022年修订）的要求，现将浙江圣达生物药业股份 有限公司（以下简称"公司"）2025年第二季度主要经营数据披露如下： 一、报告期 ...

Core Viewpoint - The article discusses the construction project of a collagen production line by Shandong Furida Biotechnology Co., Ltd., highlighting its investment, production capacity, and timeline for completion [2]. Summary by Sections Project Progress - Shandong Furida Biotechnology Co., Ltd. is expanding its collagen production line, located in Linyi City, Shandong Province, with a total investment of 12 million yuan, including 500,000 yuan for environmental protection [2]. - The project will utilize existing facilities and is expected to produce 200 kg of collagen annually upon completion in June 2025 [2]. Existing Project Status - The company has several ongoing projects, including: - Sodium hyaluronate project with an annual output of 50 tons [4]. - Various fermentation projects with different production capacities, including: - Recombinant Type II collagen: 115.2 kg/a - Recombinant Type XVII collagen: 64 kg/a - Recombinant Type III transmembrane collagen: 20.8 kg/a - The total annual production capacity for collagen will reach 200 kg [3][4]. Industry Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22, 2025, in Ningbo, Zhejiang Province, focusing on AI and bio-manufacturing, green chemicals, new materials, future food, and agriculture [8][9].

Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]